vs
Embecta Corp.（EMBC）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是Embecta Corp.的1.8倍（$461.6M vs $261.2M），Embecta Corp.净利率更高（16.9% vs 14.6%，领先2.3%），RBC Bearings INC同比增速更快（17.0% vs -0.3%），RBC Bearings INC自由现金流更多（$99.1M vs $16.6M），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
EMBC vs RBC — 直观对比
营收规模更大
RBC
是对方的1.8倍
$261.2M
营收增速更快
RBC
高出17.3%
-0.3%
净利率更高
EMBC
高出2.3%
14.6%
自由现金流更多
RBC
多$82.5M
$16.6M
两年增速更快
RBC
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $461.6M |
| 净利润 | $44.1M | $67.4M |
| 毛利率 | 61.9% | 44.3% |
| 营业利润率 | 31.9% | 22.3% |
| 净利率 | 16.9% | 14.6% |
| 营收同比 | -0.3% | 17.0% |
| 净利润同比 | — | 16.4% |
| 每股收益（稀释后） | $0.74 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCRBC
| Q4 25 | $261.2M | $461.6M | ||
| Q3 25 | $264.0M | $455.3M | ||
| Q2 25 | $295.5M | $436.0M | ||
| Q1 25 | $259.0M | $437.7M | ||
| Q4 24 | $261.9M | $394.4M | ||
| Q3 24 | $286.1M | $397.9M | ||
| Q2 24 | $272.5M | $406.3M | ||
| Q1 24 | $287.2M | $413.7M |
净利润EMBCRBC
| Q4 25 | $44.1M | $67.4M | ||
| Q3 25 | $26.4M | $60.0M | ||
| Q2 25 | $45.5M | $68.5M | ||
| Q1 25 | $23.5M | $72.7M | ||
| Q4 24 | $0 | $57.9M | ||
| Q3 24 | $14.6M | $54.2M | ||
| Q2 24 | $14.7M | $61.4M | ||
| Q1 24 | $28.9M | — |
毛利率EMBCRBC
| Q4 25 | 61.9% | 44.3% | ||
| Q3 25 | 60.0% | 44.1% | ||
| Q2 25 | 66.7% | 44.8% | ||
| Q1 25 | 63.4% | 44.2% | ||
| Q4 24 | 60.0% | 44.3% | ||
| Q3 24 | 60.7% | 43.7% | ||
| Q2 24 | 69.8% | 45.3% | ||
| Q1 24 | 64.6% | 43.1% |
营业利润率EMBCRBC
| Q4 25 | 31.9% | 22.3% | ||
| Q3 25 | 21.4% | 21.5% | ||
| Q2 25 | 31.8% | 23.2% | ||
| Q1 25 | 24.3% | 23.0% | ||
| Q4 24 | 11.0% | 21.7% | ||
| Q3 24 | 9.2% | 21.6% | ||
| Q2 24 | 20.5% | 24.0% | ||
| Q1 24 | 13.6% | 22.8% |
净利率EMBCRBC
| Q4 25 | 16.9% | 14.6% | ||
| Q3 25 | 10.0% | 13.2% | ||
| Q2 25 | 15.4% | 15.7% | ||
| Q1 25 | 9.1% | 16.6% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | 5.1% | 13.6% | ||
| Q2 24 | 5.4% | 15.1% | ||
| Q1 24 | 10.1% | — |
每股收益（稀释后）EMBCRBC
| Q4 25 | $0.74 | $2.13 | ||
| Q3 25 | $0.44 | $1.90 | ||
| Q2 25 | $0.78 | $2.17 | ||
| Q1 25 | $0.40 | $2.33 | ||
| Q4 24 | $0.00 | $1.82 | ||
| Q3 24 | $0.24 | $1.65 | ||
| Q2 24 | $0.25 | $1.90 | ||
| Q1 24 | $0.50 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $-613.1M | $3.3B |
| 总资产 | $1.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资EMBCRBC
| Q4 25 | $201.3M | $107.6M | ||
| Q3 25 | $225.5M | $91.2M | ||
| Q2 25 | $230.6M | $132.9M | ||
| Q1 25 | $209.3M | $36.8M | ||
| Q4 24 | $210.0M | — | ||
| Q3 24 | $267.5M | — | ||
| Q2 24 | $275.1M | $76.8M | ||
| Q1 24 | $299.8M | $63.5M |
总债务EMBCRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益EMBCRBC
| Q4 25 | $-613.1M | $3.3B | ||
| Q3 25 | $-650.6M | $3.2B | ||
| Q2 25 | $-669.6M | $3.1B | ||
| Q1 25 | $-736.2M | $3.0B | ||
| Q4 24 | $-768.8M | $2.9B | ||
| Q3 24 | $-738.3M | $2.9B | ||
| Q2 24 | $-763.7M | $2.8B | ||
| Q1 24 | $-769.6M | $2.8B |
总资产EMBCRBC
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.1B | ||
| Q2 25 | $1.2B | $4.8B | ||
| Q1 25 | $1.1B | $4.7B | ||
| Q4 24 | $1.1B | $4.7B | ||
| Q3 24 | $1.3B | $4.7B | ||
| Q2 24 | $1.3B | $4.7B | ||
| Q1 24 | $1.2B | $4.7B |
负债/权益比EMBCRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $99.1M |
| 自由现金流率自由现金流/营收 | 6.4% | 21.5% |
| 资本支出强度资本支出/营收 | 0.2% | 5.0% |
| 现金转化率经营现金流/净利润 | 0.39× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCRBC
| Q4 25 | $17.2M | $122.1M | ||
| Q3 25 | $84.0M | $88.4M | ||
| Q2 25 | $81.2M | $120.0M | ||
| Q1 25 | $31.8M | — | ||
| Q4 24 | $-5.3M | $84.0M | ||
| Q3 24 | $26.6M | — | ||
| Q2 24 | $-2.1M | $97.4M | ||
| Q1 24 | $24.3M | — |
自由现金流EMBCRBC
| Q4 25 | $16.6M | $99.1M | ||
| Q3 25 | $76.7M | $71.7M | ||
| Q2 25 | $80.8M | $104.3M | ||
| Q1 25 | $31.7M | — | ||
| Q4 24 | $-6.8M | $73.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-11.8M | $88.4M | ||
| Q1 24 | $20.9M | — |
自由现金流率EMBCRBC
| Q4 25 | 6.4% | 21.5% | ||
| Q3 25 | 29.1% | 15.7% | ||
| Q2 25 | 27.3% | 23.9% | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | -2.6% | 18.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.3% | 21.8% | ||
| Q1 24 | 7.3% | — |
资本支出强度EMBCRBC
| Q4 25 | 0.2% | 5.0% | ||
| Q3 25 | 2.8% | 3.7% | ||
| Q2 25 | 0.1% | 3.6% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.6% | 2.6% | ||
| Q3 24 | 0.0% | 4.1% | ||
| Q2 24 | 3.6% | 2.2% | ||
| Q1 24 | 1.2% | — |
现金转化率EMBCRBC
| Q4 25 | 0.39× | 1.81× | ||
| Q3 25 | 3.18× | 1.47× | ||
| Q2 25 | 1.78× | 1.75× | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | 1.59× | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
